At BioCrea we turn concepts into drug candidates, creating first-in-class drugs to treat debilitating central nervous system (CNS) diseases. Through the combination of our unique discovery platforms, the use of patient-derived models and clinical data together with an experienced, visionary team, the company discovers and develops new drug candidates for pharmaceutical and biotechnology partners.
June 30, 2014
BioCrea GmbH (BioCrea), the first-in-class CNS drug discovery specialist, announced today that it has received the “Top 100” award for 2014, which confirms BioCrea as one of the most innovative SMEs in Germany. This is the second time BioCrea has been listed among the “Top 100” most outstanding drivers of innovation in the country.
May 12, 2014
BioCrea GmbH (BioCrea), the first-in-class CNS drug discovery specialist, is featured in the recent May issue of NeuroPerspective, which has published a comprehensive review of pharmacotherapies for depression.
May 09, 2014
BioCrea GmbH (BioCrea), the first-in-class CNS drug discovery specialist, today announced that Chief Executive Officer, Dr. Tom Kronbach, will present at BioTrinity 2014, Europe’s leading Biopartnering and Investment Conference, to be held on 12-14 May in London.